Clinical Trials Logo
  1. Home
  2. Helicobacter Pylori
  3. NCT05635942

Optimized-dose Amoxicillin Versus Standard-dose Amoxicillin for Quadruple Therapy in Helicobacter Pylori Eradication — Helicomatri  

Helicobacter Pylori Clinical Trial

Official title:
Prospective Randomized Trial: Comparison Between Optimized-dose Amoxicillin and Standard-dose Amoxicillin for Quadruple Therapy in the Treatment of Helicobacter Pylori Infection in Tunisian Patients

Clinical Trial Summary

The goal of this prospective randomized clinical trial is to compare the rate of Helicobacter Pylori (HP) eradication after standard or dose-optimized amoxicillin quadritherapy in patients naïve to any anti-HP treatment and with chronic HP infection documented by histological examination. The main questions it aims to answer are: - compare the eradication rate of H.Pylori after a standard concomitant quadritherapy with 2g of amoxicillin versus an optimized quadritherapy with 3g of amoxicillin, in Tunisian population - Identify different factors associated with poor therapeutic response Patients were randomly assigned to either standard quadruple therapy (Qs-14: amoxicillin 1g twice daily, clarithromycin 500mg twice daily, metronidazole 500mg twice daily and esomeprazole 40mg twice daily for 14 days), or optimized quadruple therapy (Qo-14: amoxicillin 1g three times a day, clarithromycin 500mg twice daily, metronidazole 500mg twice daily and esomeprazole 40mg twice daily for 14 days). Eradication control was performed by urea breath test.

Clinical Trial Description

This study was a prospective, randomized, single-center study conducted in the hepato-gastroenterology department of Mahmoud Matri Hospital in Ariana, in collaboration with the bacteriology and biochemistry laboratory of the same hospital, the anatomopathology department of Abderrahmen Mami Hospital in Ariana, and the private clinical analysis laboratory "Fendri". all patients aged from 18 and 65 years-old with H. pylori infection documented by pathological examination of per endoscopic gastric biopsies were recruited. This was a population of patients who had undergone upper endoscopy (UE) and in whom the search for H.Pylori was indicated, according to the European Maastrich IV recommendations. Eligible subjects were randomly assigned in a 1:1 ratio to receive either standard quadruple therapy (Qs-14) including : amoxicillin 1g twice daily ,clarithromycin 500mg twice daily ,metronidazole 500mg twice daily and esomeprazole (Medis Pharmaceutical Company) 40 mg twice daily for 14 days, or optimized quadruple therapy (Qo-14) including : amoxicillin 1g three times daily ,clarithromycin 500mg twice daily, metronidazole 500mg twice daily and esomeprazole 40 mg twice daily (Medis Pharmaceutical Company) for 14 days. Eradication control was performed by 13C-UBT at least 4 weeks after the end of the treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05635942
Study type Interventional
Source Les Laboratoires des Médicaments Stériles
Contact
Status Completed
Phase Phase 4
Start date January 29, 2019
Completion date November 1, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT02892409 - TAK-438 Bismuth Drug Interaction Study Phase 1
Completed NCT05073367 - A Study Reviewing Medical Records of Adults With Helicobacter Pylori Infections in China
Completed NCT00596401 - The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
Not yet recruiting NCT04101708 - A Comparison of High-dose Dual Therapy and Half-dose Clarithromycin-containing Bismuth Quadruple Therapy for H.P Eradication in Elderly Patients Phase 4
Recruiting NCT04029493 - The Situation of Re-infection of Helicobacter Pylori After Successful Eradication
Recruiting NCT04030715 - The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study N/A
Recruiting NCT04029415 - The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
Not yet recruiting NCT02933229 - The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study Phase 4
Not yet recruiting NCT02934048 - Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection Phase 4
Recruiting NCT05184491 - Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management Phase 4
Recruiting NCT05790525 - Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy Phase 4
Completed NCT05790512 - Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Recruiting NCT05276557 - PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study Phase 3
Recruiting NCT03177629 - H. Pylori Eradication for Moderate ITP Phase 3
Recruiting NCT05053945 - Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Recruiting NCT05449028 - Helicobacter Pylori Eradication Therapy in Portugal N/A
Recruiting NCT00306280 - Feasibility Study of Phototherapy System to Treat H Pylori N/A
Active, not recruiting NCT02675010 - Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study N/A
Withdrawn NCT00467155 - Helicobacter in The Gambia (Part 2) N/A
Completed NCT03716622 - A Comparison of Clarithromycin-based and Furazolidone-based Bismuth-containing Regimens for H. Pylori Eradication Phase 4